Cingulate, Inc. (CING)

Over the past six months, Cingulate reported its Q4 and full-year 2025 results, highlighting the acceptance of an NDA for CTx-1301 and strengthened intellectual property. The FDA accepted Cingulate's NDA for CTx-1301 and set a PDUFA date of May 31, 2026. The company announced a U.S. Notice of Allowance and additional European patent grants for CTx-1301. Cingulate closed a $12 million private placement to support its operations. Analyst ratings include maintained "Buy" recommendations from Ascendiant Capital and Roth Capital, with a consensus rating of "Hold" and an average price target of $34.50 as of May 9, 2026. Cingulate's stock price increased by 21.4% from January 1, 2026, to May 9, 2026, but decreased by 13.71% in the past month.

There is no explicit information available regarding demand seasonality for Cingulate, Inc.'s products or services, as its lead products are still under regulatory review and not yet commercialized.

Cingulate, Inc. is a clinical-stage biopharmaceutical company based in Kansas City, Kansas, focused on developing next-generation pharmaceutical products using its Precision Timed Release™ (PTR™) drug delivery platform. The company is developing treatments for central nervous system and neurobiological disorders, primarily ADHD and anxiety. Its product candidates include CTx-1301 (dexmethylphenidate HCl), CTx-1302 (dextroamphetamine), and CTx-2103.

Cingulate, Inc. is headquartered in Kansas City, Kansas, United States, and its development and commercialization efforts are primarily focused on the United States market.

Cingulate's brand reputation has been shaped by its clinical development progress and financial reporting. The acceptance of the NDA for CTx-1301 and positive Phase 3 clinical data enhance the company's standing. Strengthening its intellectual property portfolio also contributes positively. However, reported net losses and missed earnings expectations are points of concern, though some analysts maintain "Buy" ratings.

Cingulate, Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. Approximately 4.41% of Cingulate's stock is owned by institutional investors. Insiders own about 37.95% of the company's stock. Falcon Creek Capital Advisor LLC and related funds reported beneficial ownership of 28.50% of Cingulate's common stock.